Silence Therapeutics plc (FRA:XRP2)
Germany · Delayed Price · Currency is EUR | Market Cap | 419.95M +94.9% |
| Revenue (ttm) | 727.67K -97.0% |
| Net Income | -65.08M |
| EPS | -1.38 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 8.50 |
| Previous Close | 8.50 |
| Day's Range | 8.50 - 8.50 |
| 52-Week Range | 3.40 - 8.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN3... [Read more]
Financial Performance
In 2025, Silence Therapeutics's revenue was $559,000, a decrease of -98.71% compared to the previous year's $43.26 million. Losses were -$88.61 million, 95.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight
Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Silence Therapeutics (SLN) with an Overweight rating and no price target Silence is a clinical-stage biotech focused on developing siRNA...
Silence Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Silence Therapeutics (SLN) with an Overweight rating.
Silence Therapeutics Slides: Corporate presentation
Silence Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
Silence Therapeutics highlights follow-up data on divesiran at EHA 2026
Silence Therapeutics (SLN) presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran, a first-in-class siRNA therapy targeting TMPRSS6, in 21 phlebotomy-dependen...
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today ...
Silence Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The session highlighted progress on a siRNA-based pipeline, with the lead PV program nearing phase II data readout in August. The company targets durable, less frequent dosing and a strong safety profile, with phase III and commercialization preparations underway.
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today ...
Silence Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The company is advancing a robust siRNA pipeline targeting cardiometabolic and hematological diseases, with key milestones expected for divesiran (polycythemia vera) and zerlasiran (Lp(a)) in 2026. Strong clinical execution, differentiated technology, and a growing early-stage pipeline position it for significant data-driven progress over the next year.
Silence Therapeutics files $300M ordinary shares offering
16:11 EDT Silence Therapeutics (SLN) files $300M ordinary shares offering
Silence Therapeutics Registration statement: Registration filing
Silence Therapeutics filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that...
Silence Therapeutics price target lowered to $27 from $35 at Chardan
Chardan analyst Keay Nakae lowered the firm’s price target on Silence Therapeutics (SLN) to $27 from $35 and keeps a Buy rating on the shares. The firm updated the company’s…
Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year
Reports revenue $422,000 vs. $142,000 last year, “The Silence team continues to advance research supporting the broad potential of our mRNAi GOLD platform, and we remain well positioned as we…
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Silence Therapeutics Earnings release: Q1 2026
Silence Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Silence Therapeutics Quarterly report: Q1 2026
Silence Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Silence Therapeutics Slides: Corporate presentation
Silence Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Silence Therapeutics Proxy statement: Proxy filing
Silence Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financ...
Silence Therapeutics Annual report: Q4 2025
Silence Therapeutics has published its Q4 2025 annual report on March 5, 2026.
Silence Therapeutics Earnings release: Q4 2025
Silence Therapeutics released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Silence Therapeutics Annual report: Q4 2025
Silence Therapeutics has published its Q4 2025 annual report on March 5, 2026.
Silence Therapeutics CEO Craig Tooman to end employment
Silence Therapeutics (SLN) announced that Craig Tooman, who has served as the company’s president, CEO and board member since 2022, agreed by mutual consent to end his employment with the…
Silence Therapeutics Announces Leadership Changes
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the...
Silence Therapeutics Transcript: Jefferies London Healthcare Conference 2025
A proprietary siRNA platform supports three clinical programs, including phase II SLN124 for polycythemia vera and phase III-ready SLN360 for Lp(a), both showing robust efficacy and differentiated dosing. Key milestones include phase II data in Q3 2025 and strong financial runway into 2028.